Categories
Archives
- 2026
- 2025
- 2024
- 2023
Oct
14
UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of BIMZELX® (bimekizumab-bkzx)
Sep
23
UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Aug
16
UCB Elevates Hidradenitis Suppurativa Awareness with Inaugural Patient and HCP Summit with Special Appearance by Dr. Sandra Lee (AKA "Dr. Pimple Popper")
Jul
29
UCB partners with Emmy Award winner Ben Decter and Tony Award nominee Kristin Hanggi in their heartfelt musical about living with epilepsy: It's All Your Fault, Tyler Price!
Jun
20
UCB Launches Dravet Syndrome Sound of Profound Moments: Family Video Project
Jun
12
UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024
Mar
09
First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
Feb
28
UCB on Growth Path for a Decade Plus
Jan
03
ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive